NEW YORK, Sept. 29, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) from August 2, 2017 through September 11, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Health Insurance Innovations investors under the federal securities laws.
To join the Health Insurance Innovations class action, go to http://www.rosenlegal.com/cases-1207.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Health Insurance Innovations’ application for a third-party insurance administrators license with the Florida Office of Insurance Regulation was denied due in part to material errors and omissions; (2) the Florida Office of Insurance Regulation’s rejection of Health Insurance Innovations’ application for a third-party insurance administrators license could result in its losing licenses in the other states; and (3) as a result, Health Insurance Innovations’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1207.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 



